We were incorporated April 24, 2012 under the laws of the State of Nevada. We intend to engage primarily in the development of regenerative medical applications which we intend to license, develop internally or acquire outright from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-30 | 2025-09-30 | 0001493152-25-029526 | EDGAR | 38K words |
| 2025-05-13 | 2024-09-30 | 0001641172-25-009968 | EDGAR | — |
| 2023-11-20 | 2023-09-30 | 0001607062-23-000524 | EDGAR | — |
| 2022-11-15 | 2022-09-30 | 0001607062-22-000694 | EDGAR | — |
| 2021-12-22 | 2021-09-30 | 0001607062-21-000641 | EDGAR | — |
| 2021-08-04 | 2020-09-30 | 0001607062-21-000250 | EDGAR | — |
| 2021-06-21 | 2019-09-30 | 0001607062-21-000165 | EDGAR | — |
| 2018-12-27 | 2018-09-30 | 0001607062-18-000491 | EDGAR | — |
| 2018-01-05 | 2017-09-30 | 0001607062-18-000006 | EDGAR | — |
| 2016-12-21 | 2016-09-30 | 0001607062-16-001092 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-13 | 2025-12-31 | 0001493152-26-006526 | EDGAR | 17K words |
| 2025-08-11 | 2025-06-30 | 0001641172-25-022884 | EDGAR | — |
| 2025-05-28 | 2025-03-31 | 0001641172-25-012619 | EDGAR | — |
| 2025-05-16 | 2024-12-31 | 0001641172-25-011206 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001607062-24-000238 | EDGAR | — |
| 2024-04-24 | 2024-03-31 | 0001607062-24-000131 | EDGAR | — |
| 2024-01-19 | 2023-12-31 | 0001607062-24-000033 | EDGAR | — |
| 2023-07-25 | 2023-06-30 | 0001607062-23-000371 | EDGAR | — |
| 2023-04-18 | 2023-03-31 | 0001607062-23-000215 | EDGAR | — |
| 2023-01-19 | 2022-12-31 | 0001607062-23-000028 | EDGAR | — |
| 2022-07-22 | 2022-06-30 | 0001607062-22-000477 | EDGAR | — |
| 2022-04-21 | 2022-03-31 | 0001607062-22-000295 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-04 | 0001493152-26-008837 | EDGAR | 1K words |
| 2026-02-02 | 0001493152-26-004733 | EDGAR | — |
| 2026-01-21 | 0001493152-26-002956 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022185 | EDGAR | — |
| 2025-10-03 | 0001493152-25-016767 | EDGAR | — |
| 2025-09-19 | 0001493152-25-014182 | EDGAR | — |
| 2025-08-07 | 0001641172-25-022575 | EDGAR | — |
| 2025-08-01 | 0001641172-25-021882 | EDGAR | — |
| 2025-06-11 | 0001641172-25-014652 | EDGAR | — |
| 2025-05-13 | 0001641172-25-009967 | EDGAR | — |
195 total filings indexed. 163 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001589150 |
| Ticker | RGBP |
| Exchange | OTC |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report